10-Q: Keros Therapeutics Reports Q2 2026 Financials

Keros Therapeutics, Inc. filed its Form 10-Q for the quarter ended June 30, 2026, detailing ongoing clinical development, financial performance, and risk factors.

Summary

• Keros Therapeutics, Inc. reported its financial results for the second quarter and first half of 2026, highlighting continued investment in research and development for its product candidates, rinvatercept and elritercept.
• The company experienced a net loss of $28.7 million for the three months ended June 30, 2026, and $52.4 million for the six months ended June 30, 2026.
• Total revenue for the three months ended June 30, 2026, was $0, a decrease from $18.2 million in the prior year period, primarily due to the recognition of service and other revenue under the Takeda Agreement in the prior year.
• Research and development expenses decreased to $22.3 million for the three months ended June 30, 2026, from $43.5 million in the same period of 2025, largely due to reduced elritercept-related expenses as activities transitioned to Takeda.
• General and administrative expenses also decreased to $8.6 million for the three months ended June 30, 2026, from $14.5 million in the prior year period.
• As of June 30, 2026, Keros Therapeutics had $257.6 million in cash and cash equivalents, which management believes is sufficient to fund operations into the first half of 2028.
• The company announced a $20 million development milestone payment from Takeda in July 2026 related to the elritercept ELRiSE MDS clinical trial.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to significant net losses and ongoing cash burn, despite progress in clinical trials and strategic partnerships.

Positives

• Continued progress in clinical development for rinvatercept (KER-065) for Duchenne muscular dystrophy and amyotrophic lateral sclerosis.
• Advancement of elritercept (KER-050) for myelodysplastic syndromes and myelofibrosis, with a $20 million milestone payment received from Takeda in July 2026.
• Sufficient cash reserves of $257.6 million as of June 30, 2026, expected to fund operations into the first half of 2028.
• Reduction in R&D and G&A expenses compared to the prior year period, indicating improved cost management.

Negatives

• Significant net loss of $28.7 million for the quarter and $52.4 million for the six months ended June 30, 2026.
• Zero revenue generated in the current quarter, compared to $18.2 million in the prior year quarter, due to the nature of milestone-based revenue recognition.
• Accumulated deficit of $534.2 million as of June 30, 2026.
• Continued expectation of operating losses and negative operating cash flows for the foreseeable future.

Risks

• The company has a limited operating history and has incurred net losses in almost every year since its inception, with anticipation of continued future losses.
• Substantial additional funding will be required to complete the development and commercialization of product candidates; failure to obtain this capital may force delays or reductions in operations.
• The company is heavily dependent on the success of its product candidates in clinical development, and any failure or significant delays could materially harm the business.
• Clinical trials are lengthy, expensive, and have uncertain outcomes; delays or inability to complete development of rinvatercept, elritercept, or other candidates are significant risks.
• Competition from other biotechnology and pharmaceutical companies could negatively impact operating results.
• Reliance on third parties for clinical trials and manufacturing introduces risks of failure to meet contractual duties or deadlines.
• The company's ability to protect its intellectual property is crucial, and it may not be able to ensure adequate protection.
• Public health crises could adversely impact the timing or results of preclinical studies and clinical trials.

Future Outlook

The company expects to continue incurring operating losses and negative operating cash flows for the foreseeable future as it advances its product candidates through development. Management believes current cash reserves are sufficient to fund operations into the first half of 2028.

Management Comments

• Management believes that the Company's existing cash and cash equivalents as of June 30, 2026 will allow the Company to continue its operations for at least the next 12 months.
• In the absence of a significant source of recurring revenue, the continued viability of the Company is dependent on its ability to continue to raise additional capital to finance its operations.
• We expect research and development expenses to fluctuate from quarter to quarter depending on the timing of clinical trial activities, clinical manufacturing and other development activities.

Industry Context

StockSavvy.ai notes that Keros Therapeutics operates in the highly competitive clinical-stage biopharmaceutical sector, where significant investment in R&D is required, and success is contingent on clinical trial outcomes and regulatory approvals. The company's focus on TGF-beta signaling pathways places it in a specialized but potentially high-reward area of drug development.

Comparison to Industry Standards

• The company's net loss of $52.4 million for the first half of 2026 is substantial, but not unusual for clinical-stage biopharmaceutical companies investing heavily in pipeline development.
• The cash burn rate, while significant, is managed with a cash runway extending into mid-2028, which is a critical metric for investors in this sector.
• The reliance on licensing agreements (Takeda, Hansoh) for significant upfront and potential milestone payments is a common strategy to fund R&D and de-risk development, aligning with industry practices.

Legal Proceedings

• The company is not currently a party to any material arbitration or legal proceedings.

Stakeholder Impact

• Shareholders may experience dilution if the company needs to raise additional capital through equity offerings.
• The company's ability to fund its operations and development programs impacts its long-term viability, affecting shareholder value.
• The success of clinical trials and potential commercialization of product candidates will directly impact future revenue streams and potential returns for shareholders.

Next Steps

• Announce initial data from the Phase 2 clinical trial of rinvatercept in patients with Duchenne muscular dystrophy in the first half of 2027.
• Engage with regulators on the design of a Phase 2 clinical trial of rinvatercept in patients with amyotrophic lateral sclerosis in the second half of 2026.
• Continue development of elritercept (KER-050) in collaboration with Takeda for myelodysplastic syndromes and myelofibrosis.

Key Dates

Recommendation

Keros Therapeutics is a clinical-stage biopharmaceutical company with promising pipeline candidates but significant financial risks. The company has a substantial cash runway, but the ongoing net losses and the need for future capital raises, coupled with the inherent uncertainties of drug development, warrant a cautious 'hold' rating. Investors should monitor clinical trial progress and financing activities closely.

Keywords

biopharmaceutical, clinical-stage, drug development, rinvatercept, elritercept, Duchenne muscular dystrophy, myelodysplastic syndromes, amyotrophic lateral sclerosis